OA12168A - Vaccine for the prophylactic or therapeutic immunization against HIV. - Google Patents

Vaccine for the prophylactic or therapeutic immunization against HIV. Download PDF

Info

Publication number
OA12168A
OA12168A OA1200200228A OA1200200228A OA12168A OA 12168 A OA12168 A OA 12168A OA 1200200228 A OA1200200228 A OA 1200200228A OA 1200200228 A OA1200200228 A OA 1200200228A OA 12168 A OA12168 A OA 12168A
Authority
OA
OAPI
Prior art keywords
gly
glu
leu
pro
ser
Prior art date
Application number
OA1200200228A
Other languages
English (en)
Inventor
Gerald Voss
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002200A external-priority patent/GB0002200D0/en
Priority claimed from GB0009336A external-priority patent/GB0009336D0/en
Priority claimed from GB0013806A external-priority patent/GB0013806D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of OA12168A publication Critical patent/OA12168A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200200228A 2000-01-31 2001-01-29 Vaccine for the prophylactic or therapeutic immunization against HIV. OA12168A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002200A GB0002200D0 (en) 2000-01-31 2000-01-31 Novel use
GB0009336A GB0009336D0 (en) 2000-04-14 2000-04-14 Novel use
GB0013806A GB0013806D0 (en) 2000-06-06 2000-06-06 Novel use

Publications (1)

Publication Number Publication Date
OA12168A true OA12168A (en) 2006-05-08

Family

ID=27255504

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200228A OA12168A (en) 2000-01-31 2001-01-29 Vaccine for the prophylactic or therapeutic immunization against HIV.

Country Status (23)

Country Link
US (3) US20030158134A1 (sk)
EP (1) EP1251870A2 (sk)
JP (1) JP2003529559A (sk)
KR (2) KR100808348B1 (sk)
CN (1) CN1326873C (sk)
AP (1) AP2002002592A0 (sk)
AU (1) AU783005B2 (sk)
BG (1) BG106964A (sk)
BR (1) BR0107972A (sk)
CA (1) CA2398611A1 (sk)
CZ (1) CZ20022643A3 (sk)
DZ (1) DZ3286A1 (sk)
EA (1) EA200200724A1 (sk)
HK (1) HK1051317A1 (sk)
HU (1) HUP0204250A3 (sk)
IL (1) IL150756A0 (sk)
MX (1) MXPA02007413A (sk)
NO (1) NO20023616L (sk)
NZ (1) NZ520327A (sk)
OA (1) OA12168A (sk)
PL (1) PL211762B1 (sk)
SK (1) SK11122002A3 (sk)
WO (1) WO2001054719A2 (sk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
MXPA02007478A (es) 2000-02-04 2004-08-23 Univ Duke Vacuna contra el virus de inmunodeficiencia humana.
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
EP3108899A1 (en) 2001-11-21 2016-12-28 The Trustees of the University of Pennsylvania Simian adenovirus adsv1 nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
CN1982332A (zh) 2002-05-16 2007-06-20 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
CN1650012A (zh) 2002-07-24 2005-08-03 英特塞尔股份公司 来自致病病毒的备选阅读框所编码的抗原
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
CN1764473A (zh) * 2003-03-24 2006-04-26 英特塞尔股份公司 矾与Th1免疫应答诱导佐剂用于增强免疫应答的用途
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
WO2005070041A2 (en) * 2004-01-09 2005-08-04 Morehouse School Of Medicine Modulating vaccine against hiv nef protein-induced lymphocyte depletion
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
HUE027837T2 (en) 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
WO2008094188A2 (en) * 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
US20100285106A1 (en) * 2006-11-17 2010-11-11 Haynes Barton F Multicomponent vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
MX2009009342A (es) * 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US8685387B2 (en) 2007-11-28 2014-04-01 The Trustees Of The University Of Pennsylvania Simian E adenoviruses SAdV-39, -25.2, -26, -30, -37, and -38
KR101614369B1 (ko) 2007-11-28 2016-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 c 아데노바이러스 sadv-40, -31, 및 -34 및 그것의 사용
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
ES2552688T3 (es) 2008-10-31 2015-12-01 The Trustees Of The University Of Pennsylvania Adenovirus de simio con proteínas de la cápside hexónica de SAdV-46 y usos del mismo
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
US8846031B2 (en) 2009-05-29 2014-09-30 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
DK3142750T3 (da) 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
CN104001155B (zh) * 2014-06-12 2016-04-13 中山大学 一种Tat蛋白及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3565535A4 (en) * 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
EP4329885A1 (en) 2021-04-27 2024-03-06 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
EP0814834B2 (fr) * 1995-03-08 2009-03-18 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Also Published As

Publication number Publication date
AU783005B2 (en) 2005-09-15
KR100808348B1 (ko) 2008-02-27
JP2003529559A (ja) 2003-10-07
NO20023616L (no) 2002-09-17
WO2001054719A3 (en) 2001-12-20
CN1326873C (zh) 2007-07-18
CA2398611A1 (en) 2001-08-02
US20090104229A1 (en) 2009-04-23
IL150756A0 (en) 2003-02-12
US20050266025A1 (en) 2005-12-01
AP2002002592A0 (en) 2002-09-30
BR0107972A (pt) 2002-11-05
MXPA02007413A (es) 2004-07-30
NZ520327A (en) 2004-06-25
KR20070073987A (ko) 2007-07-10
DZ3286A1 (fr) 2001-08-02
EP1251870A2 (en) 2002-10-30
HK1051317A1 (zh) 2003-08-01
KR20020073569A (ko) 2002-09-27
NO20023616D0 (no) 2002-07-30
BG106964A (bg) 2004-01-30
CZ20022643A3 (cs) 2003-02-12
EA200200724A1 (ru) 2003-02-27
PL211762B1 (pl) 2012-06-29
HUP0204250A3 (en) 2005-06-28
CN1419456A (zh) 2003-05-21
WO2001054719A2 (en) 2001-08-02
AU5791001A (en) 2001-08-07
PL357210A1 (en) 2004-07-26
HUP0204250A1 (hu) 2003-03-28
US20030158134A1 (en) 2003-08-21
SK11122002A3 (sk) 2003-01-09

Similar Documents

Publication Publication Date Title
AU783005B2 (en) Novel use
EP2130921B1 (en) Vaccine for prevention and treatment of HIV-infection
US20080102085A1 (en) Vaccine comprising gp120 and nef and/or tat for the immunization against hiv
KR20100109555A (ko) 백신
ZA200205968B (en) Vaccine for the prophylactic or therapeutic immunization against HIV.
TW200940094A (en) Vaccine